Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for central nervous system diseases. Its lead program, roluperidone, is being developed for negative symptoms in schizophrenia, and the company is still in the clinical/regulatory stage with no approved products or product revenue.

36.28

36.28

— Minerva Neurosciences, Inc.
%
Lead CNS drug candidate0% Roluperidone, the company's lead asset, is being developed for negative symptoms in schizophrenia.
Clinical development programs100% Preclinical and clinical-stage development work for proprietary CNS compounds and trial execution.
Regulatory and approval activities0% FDA interactions, NDA preparation, and confirmatory trial planning to support potential approval.
Future commercialization0% Potential sales, distribution, and marketing of approved products through direct or partnered channels.

Minerva does not currently sell approved products, so its near-term 'customers' are primarily regulators, clinical...

  • Regulatorsprimary

    FDA and other agencies review the NDA, trial design, and safety/efficacy data needed for approval.

  • Clinical trial ecosystemprimary

    Investigators, CROs, and trial sites execute the Phase 3 confirmatory study and related development work.

  • Schizophrenia patientsprimary

    Patients with stable negative symptoms and stable positive symptoms are the target population for roluperidone trials.

  • Psychiatrists and specialty prescriberssecondary

    If approved, these physicians would prescribe roluperidone for patients with negative symptoms in schizophrenia.

  • Payors and healthcare systemssecondary

    These buyers and gatekeepers would influence reimbursement and adoption after approval.

The company is headquartered in Burlington, Massachusetts and is listed on Nasdaq Capital Market in the United States...

  • •Headquartered in Burlington, Massachusetts, United States
  • •Nasdaq Capital Market listing under ticker NERV
  • •Priority commercialization markets include the U.S., EU, Asia and Latin America
  • •No in-house manufacturing; relies on third-party contract manufacturers
  • •Most of Asia is outside its commercialization rights for roluperidone

Minerva's strategy is to complete the additional Phase 3 confirmatory trial for roluperidone, address the FDA's...

01
Complete the C19 confirmatory Phase 3 trialshort-term

The FDA CRL means approval depends on additional clinical evidence.

02
Resubmit the roluperidone NDAshort-term

A successful resubmission is required to move from development to commercialization.

03
Build a lean commercialization modelmedium-term

The company has no current sales force and would need efficient market access if approved.

04
Preserve liquidity and reduce burnshort-term

The company has limited cash and no product revenue, so funding discipline is critical.

The company faces high clinical and regulatory risk because roluperidone has already received an FDA Complete Response...

critical

Regulatory setback for roluperidone

The FDA issued a Complete Response Letter, and approval now depends on additional confirmatory data.

Scope
Lead program
Materiality
high
high

Clinical trial failure or delay

The company must execute a new Phase 3 study successfully to support resubmission.

Scope
C19 confirmatory trial
Materiality
high
high

Liquidity and financing risk

The company has no product sales and limited cash, so it may need further capital before commercialization.

Scope
Corporate funding
Materiality
high
medium

Commercial execution risk

It currently has no marketing or sales organization and would need to build one or partner externally.

Scope
Future launch
Materiality
medium
medium

Manufacturing and supply chain dependence

All manufacturing is outsourced, creating reliance on third-party capacity, quality, and timelines.

Scope
Clinical and future commercial supply
Materiality
medium
Research and development expense recognition
Affects operating loss and quarterly volatility
Liability related to sale of future royalties
Affects balance sheet classification and future non-cash income recognition
Goodwill impairment
Potential non-cash charge to earnings
Clinical trial accruals and estimates
Can shift expense timing across quarters

NEUROONE MEDICAL TECHNOLOGIES Corp

NMTC · Surgical & Medical Instruments & Apparatus

Minerva Gold Inc.

Metal Mining

JUPITER NEUROSCIENCES, INC.

JUNS · Pharmaceutical Preparations

ZEVRA THERAPEUTICS, INC.

ZVRA · Pharmaceutical Preparations

Neumora Therapeutics, Inc.

NMRA · Biological Products, (No Diagnostic Substances)

COGNITION THERAPEUTICS INC

CGTX · Biological Products, (No Diagnostic Substances)

: 28.4.2026